New triazoles and echinocandins: Mode of action, in vitro activity and mechanisms of resistance

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 981-998

  Fera, Maria Teresa ^a   La Camera, Erminia ^a   De Sarro, Angelina ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Albaconazole; Anidulafungin; Caspofungin; Isavuconazole; Micafungin; Posaconazole; Ravuconazole; Voriconazole

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALBACONAZOLE; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ERGOSTEROL; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL ABSCESS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; BASIDIOMYCETES; BINDING AFFINITY; BIOSYNTHESIS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CRYPTOCOCCUS; CUNNINGHAMELLA; DRUG INDICATION; DRUG MECHANISM; ESOPHAGITIS; FUNGUS ISOLATION; FUSARIUM; HUMAN; IN VITRO STUDY; MALASSEZIA; MINIMUM INHIBITORY CONCENTRATION; MOULD; MUCOR; MYCOSIS; NONHUMAN; PERITONITIS; PLEURISY; PROTEIN MODIFICATION; REVIEW; RHIZOPUS; RHODOTORULA; TRICHOSPORON; TRYPANOSOMA CRUZI; ZYGOMYCETES;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 70350593957     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.67     Document Type: Review

References (181)

1. Walsh TJ, Groll A, Hiemenz J, Fleming R, Rpilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(1), 48-66 (2004).
2. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12(1), 40-79 (1999).
3. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42(10), 4419-4431 (2004).
4. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)β-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. 49(7), 2851-2856 (2005).
5. Arikan S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 46(9), 3084-3087 (2002). (Pubitemid 34898703)
6. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61(1), 19-30 (2008).
7. Lemke A, Kiderlen AF, Kayser O. Amphotericin B. Appl. Microbiol. Biotechnol. 68(2), 151-162 (2005).
8. Zonios DI, Bennett JE. Update on azole antifungals. Semin. Respir. Crit. Care Med. 29(2), 198-210 (2008).
9. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 28(5), 614-645 (2008).
10. White T, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11(2), 382-402 (1998). (Pubitemid 28197359)
11. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12(4), 501-517 (1999).
12. Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist. Update 2(6), 390-402 (1999). (Pubitemid 30159141)
13. Akins RA. An update on antifungal targets and mechanism of resistance in Candida albicans. Med. Mycol. 43(4), 285-318 (2005).
14. Hof H. A new, broad-spectrum azole antifungal: posaconazole - mechanisms of action and resistance, spectrum of activity. Mycoses 49(1), 2-6 (2006).
15. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-α sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39, 2431-2438 (2001).
16. Kelly SL, Lamb DC, Baldwin BC, Corran AJ, Kelly DE. Characterization of Saccharomyces cerevisiae CYP61, sterol δ22-desaturase, and inhibition by azole antifungal agents. J. Biol. Chem. 272(15), 9986-9988 (1997).
17. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PA. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem. Soc. Trans. 18(1), 56-59 (1990).
18. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutaded forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrobial. Agents Chemother. 48(2), 568-574 (2004). (Pubitemid 38141718)
19. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. 46(2), 229-234 (2000). (Pubitemid 30639292)
20. VFEND (voriconazole) tablets and injection; package insert. Pfizer Inc., NY, USA (2002).
21. Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43(12), 5848-5859 (2005).
22. Espinel-Ingroff A, Fothergill A, Ghannoum M et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43(10), 5243-5246 (2005). (Pubitemid 41484032)
23. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J. Antimicrob. Chemother. 55(6), 914-920 (2005). (Pubitemid 40883176)
24. Cantón E, Pemán J, Valentín A, Bosch M, Espinel-Ingroff A, Gobernado M. Comparison of posaconazole and voriconazole in vitro killing against Candida krusei. Diagn. Microbiol. Infect. Dis. 62(2), 177-181 (2008).
25. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 44(7), 1917-1920 (2000).
26. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activity of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of Zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52(4), 1396-1400 (2008).
27. Mandras N, Tullio V, Allizond V et al. In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy. Antimicrobial Agents Chemother. 53(4), 1657-1659 (2009).
28. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46(6), 1723-1727 (2002).
29. Diekema DJ, Messer SA, Hollis RJ et al. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63(2), 233-236 (2009).
30. Enache-Angoulvant A, Girard A, Poirot JL, Hennequin C. In vitro activity of caspofungin and voriconazole against uncommon Candida spp. Int. J. Antimicrob. Agents. 33(6), 595-596 (2009).
31. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48(3), 201-205 (2004).
32. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol. 44(5), 1782-1787 (2006).
33. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43(5), 2163-2167 (2005). (Pubitemid 40656221)
34. Bernal-Martinez L, Gomez-Lopez A, Castelli MV et al. Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cyptococcus species and literature review. Med. Mycol. 23, 1-7 (2009).
35. Pfaller MA, Diekema DJ, Gibbs DL et al. Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities to noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47(1), 117-123 (2009).
36. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 50(6), 447-450 (2007). (Pubitemid 47609822)
37. Guinea J, Recio S, Peláez T, Torres-Narbona M, Bouza E. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob. Agents Chemother. 52(9), 3444-3446 (2008).
38. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44(6), 1734-1736 (2000).
39. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39(3), 954-958 (2001). (Pubitemid 32209706)
40. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. 45(9), 2635-2637 (2001).
41. Lacroix C, de Chauvin MF. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. J. Antimicrob. Chemother. 61(4), 835-837 (2008).
42. Pawlik B, Szul A, Macura AB. Susceptibility of fungi isolated from clinical materials to voriconazole. Med. Dosw Mikrobiol. 58(2), 155-161 (2006).
43. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J. Clin. Microbiol. 39(1), 385-388 (2001). (Pubitemid 32059628)
44. Carrillo-Muñoz AJ, Giusiano G, Guarro J et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int. J. Antimicrob. Agents 30(2), 157-161 (2007).
45. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50(6), 2009-2015 (2006). • Large, multicentre study. Posaconazole showed potent in vitro activity against a globally diverse collection of clinically important strains of yeast and molds, and was frequently more active than other azoles and amphotericin B.
46. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzan A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50(3), 917-921 (2006). (Pubitemid 43327795)
47. Pfaller MA, Messer SA, Boyken L et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J. Clin. Microbiol. 42(7), 3142-3146 (2004). (Pubitemid 38938071)
48. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46(2), 551-559 (2008).
49. Sóczó G, Kardos G, McNicholas PM et al. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J. Antimicrob. Chemother. 60(5), 1004-1009 (2007). (Pubitemid 47617747)
50. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45(10), 2862-2864 (2001).
51. Lortholary O, Dannaoui E, Raoux D et al. In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 51(9), 3378-3380 (2007).
52. Almvroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51(7), 2587-2590 (2007). (Pubitemid 47047341)
53. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela JL. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 53(4), 1686-1689 (2009).
54. Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J. Clin. Microbiol. 44(10), 3616-3622 (2006).
55. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46(5), 1581-1582 (2002).
56. Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob. Agents Chemother. 52(7), 2683-2685 (2008).
57. Iqbal NJ, Boey A, Park BJ, Brandt ME. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. Diagn. Microbiol. Infect. Dis. 62(3), 348-350 (2008).
58. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58(6), 612-624 (2004). (Pubitemid 38996992)
59. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41(8), 3623-3626 (2003).
60. Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 53(2), 794-795 (2009).
61. Gonzàlez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. 43(3), 281-284 (2005). (Pubitemid 40867502)
62. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med. Mycol. 46(6), 567-573 (2008).
63. Ramani R, Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia 163(6), 315-319 (2007). (Pubitemid 46919105)
64. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51(5), 1818-1821 (2007).
65. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52(4), 1580-1582 (2008).
66. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53(1), 309-311 (2009).
67. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57(1), 135-138 (2006). (Pubitemid 43057070)
68. Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European Committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 53(4), 1645-1647 (2009).
69. González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med. Mycol. 47(1), 71-76 (2009).
70. Gomez-Lopez A, Mellado E, Rodriguez- Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J. Antimicrob. Chemother. 55(3), 312-316 (2005).
71. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44(10), 2883-2886 (2000).
72. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48(2), 101-105 (2004).
73. Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. 35(2), 163-167 (1999). (Pubitemid 29525559)
74. Moore CB, Walls CM, Denning W. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. 44(2), 441-443 (2000).
75. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of ravuconazole and four other antifungal agents against fluconazole - resistant or - susceptible clinical yeast isolates. Antimicrob. Agents Chemother. 48(8), 3107-3111 (2004). (Pubitemid 38989181)
76. St-Germain G, Laverdière M, Pelletier R et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19(1), 55-62 (2008).
77. Trilles L, Fernández-Torres B, Lazéra Mdos S, Wanke B, Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42(10), 4815-4817 (2004).
78. Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. 9(12), 1250-1252 (2003). (Pubitemid 38028881)
79. Gilgado F, Serena C, Cano J, Gené J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother. 50(12), 4211-4213 (2006).
80. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J. Antimicrob. Chemother. 61(4), 805-809 (2008).
81. Castelli MV, Alastruey-Izquierdo A, Cuesta I et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob. Agents Chemother. 52(8), 2926-2928 (2008).
82. Bartroli J, Turmo E, Alguero M et al. New azole antifungals. 3. synthesis and antifungal activity of 3-substituted-4(3H)- quinazolinones. J. Med. Chem. 41(11), 1869-1882 (1998).
83. Ramos G, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. 44(2), 283-286 (1999). (Pubitemid 29389293)
84. Miller JL, Schell WA, Wills EA et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 48(2), 384-387 (2004).
85. Morera-López Y, Torres-Rodríguez JM, Jiménez-Cabello T et al. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. 43(6), 505-510 (2005). (Pubitemid 41700943)
86. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis. 48(1), 69-71 (2004). (Pubitemid 38167503)
87. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45(7), 2151-2153 (2001). (Pubitemid 32591717)
88. Garau M, Pereiro M Jr, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob. Agents Chemother. 47(7), 2342-2344 (2003). (Pubitemid 36753598)
89. Urbina JA, Lira R, Visbal G, Bartrolí J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44(9), 2498-2502 (2000); erratum in: Antimicrob. Agents Chemother. 44(10), 2924 (2000).
90. Rogers TR. Antifungal drug resistance: limited data, dramatic impact? Int. J. Antimicrob. Agents 27(1), 7-11 (2006).
91. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. Mode of action and resistance to azole antifungals associated with the formation of 14-α-methylergosta-8,24(28)- dien-3-β,6-α-diol. Biochem. Biophys. Res. Commun. 207(3), 910-915 (1995).
92. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41(7), 1482-1487 (1997).
93. White TC. The presence of an R467K amino acid substitution and lossof allelic variation correlate with an azole-resistant lanosterol 14-demethylase in Candida albicans. Antimicrob. Agents Chemother. 41(7), 1488-1494 (1997).
94. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2(2), 73-85 (2002).
95. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35(9), 1073-1080 (2002).
96. Sanglard D, Ischer F, Calabrese D, De Micheli M, Bille J. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist. Updat. 1(4), 255-265 (1998).
97. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22(2), 291-321 (2009). •• Evaluated fungal efflux-mediated drug resistance. A possible strategy to overcome effects due to efflux upregulation is envisaged.
98. Niimi M, Niimi K, Takano Y et al. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J. Antimicrob. Chemother. 54(6), 999-1006 (2004).
99. Park S, Perlin DS. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb. Drug Resist. 11(39), 232-238 (2005).
100. Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 47(4), 1220-1227 (2003).
101. Liu TT, Znaidi S, Barker KS et al. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot. Cell. 6(11), 2122-2138 (2007). (Pubitemid 350221281)
102. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39(11), 2378-2386 (1995).
103. Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42(10), 2584-2589 (1998).
104. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47(10), 3149-3154 (2003). (Pubitemid 37229571)
105. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49(2), 668-679 (2005). (Pubitemid 40175679)
106. Pfaller MA, Messer SA, Boyken L et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42(7), 3137-3141 (2004). •• Addressed the issue of cross-resistance between fluconazole and ravuconazole, and the use of fluconazole as a surrogate marker to predict the susceptibility of Candida spp. to ravuconazole (and likely to other extended-spectrum triazoles). (Pubitemid 38938070)
107. Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob. Agents Chemother. 49(2), 783-787 (2005). (Pubitemid 40175697)
108. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chemother. 50(7), 2374-2383 (2006).
109. Sanglard D, Ischer F, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 45(4), 1174-1183 (2001). (Pubitemid 32230999)
110. Löffler J, Einsele H, Hebart H, Schumacher U, Hrastnik C, Daum G. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains. FEMS Microbiol. Lett. 185(1), 59-63 (2000). (Pubitemid 30145607)
111. Marichal P, Vanden Bossche H, Odds FC et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 41(10), 2229-2237 (1997). (Pubitemid 27422218)
112. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42(2), 241-253 (1998).
113. Marichal P, Koymans L, Willemsens S et al. Contribution of mutations in the cytochrome P450 14 ademethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145(Pt 10), 2701-2713 (1999). (Pubitemid 29485885)
114. Loffler J, Kelly SL, Hebart H, Schumacher U, LassFlorl C, Einsele H. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151(2), 263-268 (1997). (Pubitemid 27293310)
115. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 44(10), 2693-2700 (2000).
116. Lamb DC, Kelly DE, Schunck WH et al. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272(9), 5682-5688 (1997).
117. Guinea J, Sánchez-Somolinos M, Cuevas O, Peláez T, Bouza E. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med. Mycol. 44(6), 575-578 (2006).
118. Fukuoka T, Johnston DA, Winslow CA et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob. Agents Chemother. 47(4), 1213-1219 (2003).
119. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob. Agents Chemother. 40(11), 2443-2446 (1996). (Pubitemid 26367622)
120. Pfaller MA, Diekema DJ, Gibbs DL et al.; Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46(2), 515-521 (2008).
121. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect Dis. 46(1), 120-128 (2008)
122. Nascimento AM, Goldman GH, Park S et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47(5), 1719-1726 (2003).
123. Mellado E, Garcia-Effron G, Buitrago MJ, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Targeted gene disruption of the 14-α sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob. Agents Chemother. 49(6), 2536-2538 (2005).
124. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. Substitutions at methionine 220 in the 14α-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48(7), 2747-2750 (2004). (Pubitemid 38823458)
125. Mellado E, Garcia-Effron G, Alcázar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51(6), 1897-904 (2007). •• Described the analysis of a new molecular mechanism responsible for a phenotype of Aspergillus fumigatus cross-resistance to azole drugs.
126. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356(14), 1481-1483 (2007). •• The prevalence of azole resistance in A. fumigatus isolates that were resistant to itraconazole is investigated.
127. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs. 12(8), 1313-1333 (2003).
128. Vicente MF, Basilio A, Cabello A, Peláez F. Microbial natural products as a source of antifungals. Clin. Microbiol. Infect. 9(1), 15-32 (2003). (Pubitemid 36511665)
129. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 64(9), 969-982 (2004).
130. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin. Ther. 27(6), 657-673 (2005).
131. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of Aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin. Infect. Dis. 46(3), 327-360 (2008).
132. Denning DW. Echinocandin antifungal drugs. Lancet 362(9390), 1142-1151 (2003).
133. Mazur P, Morin N, Baginsky W et al. Differential expression and function of two homologous subunits of yeast 1,3-β-d-glucan synthase. Mol. Cell. Biol. 15(10), 5671-5681 (1995).
134. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50(8), 2892-2894 (2006).
135. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50(6), 2058-2063 (2006). (Pubitemid 43807526)
136. Lesage G, Sdicu AM, Menard P, Shapiro J, Hussein S, Bussey H. Analysis of β-1,3- glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 167(1), 35-49 (2004). (Pubitemid 38736368)
137. Dijkgraaf GJ, Abe M, Ohya Y, Bussey H. Mutations in Fks1p affect the cell wall content of β-1,3- and β-1,6-glucan in Saccharomyces cerevisiae. Yeast 19(8), 671-690 (2002).
138. Liu J, Balasubramanian MK. 1,3-β-glucan synthase: a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 1(2), 159-169 (2001).
139. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy. Expert Opin. Pharmacother. 6(10), 1657-1668 (2005).
140. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 3(1), 71-97 (2007).
141. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 182(6), 1791-1795 (2000). (Pubitemid 30951807)
142. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts (3rd Edition). Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2007).
143. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2.500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43(11), 5425-5427 (2005). (Pubitemid 41612308)
144. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46(8), 2620-2629 (2008). •• The Clinical and Laboratory Standards Institute Antifungal Subcommittee utilized this study to propose interpretative breakpoints for the MIC testing of anidulafungin, caspofungin and micafungin against Candida species.
145. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46(1), 150-156 (2008).
146. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20(4), 121-136 (2003).
147. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44(10), 3533-3538 (2006). (Pubitemid 46768811)
148. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44(3), 760-763 (2006).
149. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51(6), 2253-2256 (2007). (Pubitemid 46903131)
150. Dannaoui E, Lortholary O, Raoux D et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52(2), 778-781 (2008). (Pubitemid 351170865)
151. Laverdiere M, Labbé AC, Restieri C et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J. Crit. Care 22(3), 245-250 (2007). (Pubitemid 47385967)
152. Ruan SY, Chu CC, Hsueh PR. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob. Agents Chemother. 52(8), 2919-2922 (2008).
153. Marco F, Danés C, Almela M et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates results from a six-year study (1996-2001). Diagn. Microbiol. Infect. 46(4), 259-264 (2003).
154. Ghannoum MA, Chen A, Buhari M et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect. 15(3), 274-279 (2009).
155. Cuenca-Estrella M, Mellado E, Díaz-Guerra TM, Monzón A, Rodríguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J. Antimicrob. Chemother. 46(3), 475-477 (2000). (Pubitemid 30706055)
156. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54(6), 1051-1056 (2004).
157. Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
158. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41(1), 403-409 (2003). (Pubitemid 36098607)
159. Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42(8), 3475-3482 (2004). (Pubitemid 39045669)
160. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52(1), 321-328 (2008).
161. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2002).
162. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45(1), 327-330 (2001). (Pubitemid 32039139)
163. Serrano Mdel C, Valverde-Conde A, Chavez MM et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. 45(2), 131-135 (2003). (Pubitemid 36263026)
164. Douglas CM. Fungal β(1,3)-D-glucan synthesis. Med Mycol. 39(1), 55-66 (2001).
165. Perlin DS. Resistance to echinocandinclass antifungal drugs. Drug Resist. Updat. 10(3), 121-130 (2007).
166. Park S, Kelly R, Nielsen Kahn J et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob. Agents Chemother. 49(8), 3264-3273 (2005).
167. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51(5), 1876-1878 (2007).
168. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57(4), 705-708 (2006).
169. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an fks1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52(6), 2263-2265 (2008). (Pubitemid 351758575)
170. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26(6), 877-880 (2006). (Pubitemid 43807639)
171. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E; European Committee on Antibiotic Susceptibility Testing. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52(9), 3092-3098 (2008).
172. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50(7), 2522-2524 (2006). (Pubitemid 43993195)
173. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. 48(1), 225-235 (2003). (Pubitemid 36411479)
174. Niimi K, Maki K, Ikeda F et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50(4), 1148-1155 (2006).
175. Pfaller MA, Messer SA, Boyken L et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. 41(12), 5729-5731 (2003).
176. Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob. Agents Chemother. 48(10), 3845-3849 (2004). (Pubitemid 39304613)
177. Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 46(8), 2462-2469 (2002).
178. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(1), 299-305 (2005).
179. Rocha EM, Garcia-Effron G, Park S, Perlin DS. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51(11), 4174-4176 (2007). (Pubitemid 350057823)
180. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro - in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52(10), 3504-3511 (2008).
181. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30(4), 251-255 (1998). (Pubitemid 28210124)